Role of Immunotherapy in developing Cardiac Toxicity
This special issue belongs to
|Research & Reviews: A Journal of Medicine
Deadline for Manuscript Submission
|March 31st, 2023
Deadline for Publication
|April 15, 2023
Special Issue Description
Immunotherapy is one of the foremost compelling and helpful choices for cancer patients. Five classes of immunotherapies, incorporate cell-based chimeric antigen receptor T-cells, checkpoint inhibitors, cancer immunizations, antibody-based focused on treatments, and oncolytic infections. Immunotherapies can progress survival rates among cancer patients. Monoclonal antibodies are manufactured proteins utilized as immunotherapies to treat and oversee cancers that require a total understanding of cancer science and the host’s safe framework.
Be that as it may, actuated safe reactions, by monoclonal antibodies, can target nonspecific cancer cells, causing immune-related adverse effects unfavorable that can lead to permanent disorders among cancer patients. The immune-related unfavorable events pose a risk of cardiac toxicity that incorporates hypertension, heart failures, arrhythmias, and dysfunction of ventricular during and after monoclonal counteracting agent immunotherapy. Additionally, with a mortality rate of 47% attributed to heart disease and cancer, it is basic to utilize dependable, delicate, and clinically important models for adequacy and security appraisal of resistant drugs for cancer and the anticipation of cardiac toxicities.
• Heart failure
• Monoclonal antibodies
Manuscript Submission information
Manuscripts should be submitted online by registering and logging in to this link. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed.
Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent on email address:[email protected] for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page.